S
Suvretta Capital Management, LLC
+ HoldingKURA
+0.50%
3M Return
$10.720
+0.888 (+8.28%)At close
Loading chart…
- High
- 10.740
- Open
- 9.740
- VWAP
- 10.38
- Volume
- 2.29M
- Mkt Cap
- 1.56B
- Low
- 9.670
- Amount
- 23.76M
- EV/EBITDA, TTM
- -1.14
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on precision medicine for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer signaling pathways. Its product candidates include KOMZIFTI (Ziftomenib), Tipifarnib, and Darlifarnib (KO-2806). Ziftomenib, is a potent, selective, reversible and oral small molecule inhibitor that blocks the interaction of two proteins, menin and the protein expressed by the Lysine K-specific Methyl Transferase 2A gene, or KMT2A gene. Ziftomenib is a selective investigational inhibitor of the menin-KMT2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias. Tipifarnib is a potent, selective and orally bioavailable farnesyl transferase inhibitor (FTI). The KO-2806 is an FTI, is being evaluated in a Phase I first-in-human trial as a monotherapy and in combination with other targeted therapies.
AI analysis of Kura Oncology Inc (KURA)
HoldKura Oncology Inc is not a strong buy at the current price of $9.61 due to its low RSI of 39.012, indicating potential weakness, and significant insider selling activity increasing by 178.01%.
Analyst Ratings (5)
+177.15% upside
Buy
5 Buy
0 Hold
0 Sell
Current: 10.72
Low
16.00
Average
29.71
High
40.00
JPMorgan
Overweight
$30
2026-10-01
JPMorgan
2026-10-01
Price Target
$30
Overweight
BofA
Buy
$31
2026-08-13
BofA
2026-08-13
Price Target
$31
Buy
Lake Street
Buy
$23
2026-04-14
Lake Street
2026-04-14
Price Target
$23
Buy
Mizuho
Outperform
$25
2026-03-24
Mizuho
2026-03-24
Price Target
$25
Outperform
UBS
Buy
$15
2026-03-13
UBS
2026-03-13
Price Target
$15
Buy
Valuation Metrics
The current forward P/E ratio for Kura Oncology Inc (KURA) is 0.00, compared to its 5-year average forward P/E of -5.64.
Whales holding KURA
Events Timeline
News
9.510-24CNBCBiotech Sector Recovery: Moderna Leads the Charge
8.510-13NewsfilterCaspian and Kura Collaborate on Next-Gen Oral Menin Inhibitor
6.010-01CNBCKura Oncology's Cancer Drug Sales Growth Sparks Stock Rally Potential
6.010-01CNBCLatest Wall Street Rating Updates
- 5.009-04Newsfilter
Kura Oncology Grants Stock Options to New Employees
KURA FAQ — answered by Alphio AI
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on precision medicine for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer signaling pathways. Its product candidates include KOMZIFTI (Ziftomenib), Tipifarnib, and Darlifarnib (KO-2806). Ziftomenib, is a potent, selective, reversible and oral small molecule inhibitor that blocks the interaction of two proteins, menin and the protein expressed by the Lysine K-specific Methyl Transferase 2A gene, or KMT2A gene. Ziftomenib is a selective investigational inhibitor of the menin-KMT2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias. Tipifarnib is a potent, selective and orally bioavailable farnesyl transferase inhibitor (FTI). The KO-2806 is an FTI, is being evaluated in a Phase I first-in-human trial as a monotherapy and in combination with other targeted therapies. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Kura Oncology Inc is not a strong buy at the current price of $9.61 due to its low RSI of 39.012, indicating potential weakness, and significant insider selling activity increasing by 178.01%.
5 analysts cover KURA: 5 rate it Buy, 0 Hold and 0 Sell. The average price target is 29.71.
Community
More ↗No posts yet
Sign up or log in to join the discussionThis page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.